A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 2554 participants.

Also called NCT06268873

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 2,554 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT06268873
  • EU CT 2023-506457-38-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, China, Czechia, Denmark, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Malaysia, Netherlands, Peru, Philippines, Poland, Romania, Saudi Arabia, Serbia, Slovakia, South Africa, South Korea, Spain, Sweden, Taiwan, Thailand, Türkiye, Ukraine, United Kingdom, Vietnam (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06268873. Randomized; quadruple masking; primary purpose treatment. Start 2024-03-29 (actual); primary completion 2028-02-24 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
Condition
Chronic Kidney Disease and Hypertension
Intervention (Drug)
Baxdrostat/dapagliflozin
Intervention (Drug)
Dapagliflozin in combination with placebo
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct06268873
Content hash
205a5bfe82bce6b102cfcefe916da6b23e1a895b0384cf0f1dfff9086c15f89a